Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

3.2K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.2K
Clinical Trials01:16

Clinical Trials

7.0K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
7.0K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

162
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
162
Issues And Trends In Healthcare Delivery System01:29

Issues And Trends In Healthcare Delivery System

5.8K
The issues and trends in healthcare delivery are constantly changing. The COVID-19 pandemic is one recent issue that wreaked havoc on healthcare systems, causing a shortage of healthcare workers, high demand for medicines and supplies, and increased medical expenditure due to a lack of insurance. Other issues include rising healthcare costs and care fragmentation.
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
5.8K
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.7K
Hazard Ratio01:12

Hazard Ratio

220
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
220

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pilot Study and Evaluation of a Sleep Health Education Program for Early High School.

The Journal of school health·2026
Same author

ToxMet: a web tool for toxicogenomic data analysis using genome-scale metabolic modeling.

Toxicological sciences : an official journal of the Society of Toxicology·2026
Same author

Quantifying the Financial Return on Investment of Risk-Based Quality Management Implementation in Clinical Development.

Therapeutic innovation & regulatory science·2026
Same author

Effectiveness of a Brief Digitized Contact-Based Intervention in Improving Mental Health Stigma and Help-Seeking in Young Adults: Mixed Methods Study.

JMIR human factors·2026
Same author

Synapse specific alterations of autophagy are a hallmark of Danon disease.

bioRxiv : the preprint server for biology·2026
Same author

Tell me lies, tell me sweet little lies: power calculations in clinical trials.

The British journal of psychiatry : the journal of mental science·2026

Related Experiment Video

Updated: Aug 28, 2025

The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living
08:36

The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living

Published on: July 28, 2022

3.9K

Assessing the Financial Value of Decentralized Clinical Trials.

Joseph A DiMasi1, Zachary Smith2, Ingrid Oakley-Girvan3

  • 1Tufts Center for the Study of Drug Development, Tufts University, 145 Harrison Avenue, Boston, MA, 02111, USA. joseph.dimasi@tufts.edu.

Therapeutic Innovation & Regulatory Science
|September 14, 2022
PubMed
Summary

Decentralized clinical trials (DCTs) offer significant financial benefits, increasing drug development value by $20 million per drug and yielding a seven-fold return on investment. These findings highlight the substantial financial advantages of adopting DCT methods.

Keywords:
Clinical development phasesDecentralized clinical trialsExpected net present valuePharmaceutical salesR&D costsReturn on investment

More Related Videos

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

1.8K
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.8K

Related Experiment Videos

Last Updated: Aug 28, 2025

The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living
08:36

The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living

Published on: July 28, 2022

3.9K
In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

1.8K
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.8K

Area of Science:

  • Clinical trial methodology
  • Pharmaceutical economics
  • Drug development

Background:

  • Decentralized clinical trials (DCTs) represent a significant shift in clinical trial practices.
  • A comprehensive financial assessment of DCTs has been lacking.

Purpose of the Study:

  • To assess the financial net benefits of employing decentralized clinical trials (DCTs).
  • To quantify the value increment and return on investment (ROI) associated with DCT implementation.

Main Methods:

  • Developed an expected net present value (eNPV) model for drug development cash flows.
  • Calculated DCT value as the increment in eNPV compared to traditional trials.
  • Utilized published data, Tufts CSDD, and Medable Inc. data for model parameters.

Main Results:

  • Substantial value was found in employing DCT methods in phase II and phase III trials.
  • An increase in value of $20 million per drug entering phase II was observed.
  • A seven-fold return on investment (ROI) was calculated for DCT implementation.

Conclusions:

  • DCTs provide significant added value for drug sponsors.
  • High returns on investment justify the adoption of DCT technologies.
  • Future research should expand data and explore additional DCT operational aspects.